Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunai and Boehringer partner to identify T-cell targets
The initial phase of the partnership, valued at up to $15m and running until 2027, may be expanded if scientific milestones are met and both parties agree. The
The initial phase of the partnership, valued at up to $15m and running until 2027, may be expanded if scientific milestones are met and both parties agree. The
Ionis will retain the responsibility for commercialising the RNA-targeted medicine within the US and will remain the global lead for development activities. Under the agreement, Recordati will handle regulatory
The authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy. It makes the combination the first regimen that pairs a programmed death-1 (PD-1)
Frazier Life Sciences led the financing round along with new investors EQT Life Sciences, Forbion, Monograph and Wellington Management. LifeArc Ventures, Oxford Science Enterprises and the University of
The partnership will combine Combotope’s SMART-Phage discovery platform with Boehringer Ingelheim’s research and development capabilities, focusing on multiple identified oncology targets. Combotope CEO Ola Blixt said: “At Combotope,
Nuvectis secured worldwide rights, outside specified Asian territories, to develop, manufacture and commercialise Haisco’s drug candidates HSK42360 and HSK39297. Haisco will receive $40m in upfront and near-term payments,
This expands intellectual property protection already in place for Genprex in jurisdictions such as China, Europe, Japan, Russia and the US. Genprex’s Reqorsa is currently in development alongside
The partnership will combine BioArctic’s BrainTransporter technology with an unidentified Lilly drug candidate. BioArctic is set to receive a $30m upfront payment. If the new product progresses successfully,
According to a regulatory filing, Sun Pharma will buy the entire issued and outstanding share capital of Innovcare Lifesciences via a cash transaction. The company expects to close
The approval follows a positive finding in the pivotal IRAKLIA Phase III study, which demonstrated non-inferior efficacy and pharmacokinetics compared with the intravenous (IV) formulation. It also marks